These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 26460822)

  • 21. Post-transplant primary central nervous system lymphoma after Epstein-Barr virus cerebellitis.
    Valencia-Sanchez C; Steenerson KK; Kelemen K; Orenstein R; Kusne S; Grill MF
    J Neurovirol; 2019 Apr; 25(2):280-283. PubMed ID: 30607891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Central nervous system lymphoproliferative disorder in pediatric kidney transplant recipients.
    Traum AZ; Rodig NM; Pilichowska ME; Somers MJ
    Pediatr Transplant; 2006 Jun; 10(4):505-12. PubMed ID: 16712612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Irradiation on Incidence of Post-Transplant Lymphoproliferative Disorder after Hematopoietic Cell Transplantation in Miniature Swine.
    Matar AJ; Patil AR; Al-Musa A; Hanekamp I; Sachs DH; Huang CA; Duran-Struuck R
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1732-8. PubMed ID: 26210443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder.
    Rouphael B; Lankireddy S; Lazaryan A; Kukla A; Ibrahim HN; Matas AJ; Issa N
    Clin Transplant; 2016 Jan; 30(1):60-5. PubMed ID: 26497471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heterogeneous Manifestations of Posttransplant Lymphoma in Renal Transplant Recipients: A Case Series.
    Patil R; Prashar R; Patel A
    Transplant Proc; 2021 Jun; 53(5):1519-1527. PubMed ID: 34134932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival.
    Serre JE; Michonneau D; Bachy E; Noël LH; Dubois V; Suberbielle C; Kreis H; Legendre C; Mamzer-Bruneel MF; Morelon E; Thaunat O
    Kidney Int; 2014 Jan; 85(1):182-90. PubMed ID: 23802193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conservative management of post-transplant central nervous system lymphoma.
    Valavoor SH; Ashraf Z; Narwal R; Ratnam S
    Int Urol Nephrol; 2013 Aug; 45(4):1219-22. PubMed ID: 22476860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-Transplant Lymphoproliferative Disorders.
    Dharnidharka VR; Ruzinova MB; Marks LJ
    Semin Nephrol; 2024 Jan; 44(1):151503. PubMed ID: 38519279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients: late onset and favorable response to treatment.
    Chan TS; Hwang YY; Gill H; Au WY; Leung AY; Tse E; Chim CS; Loong F; Kwong YL
    Clin Transplant; 2012; 26(5):679-83. PubMed ID: 22324300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcineurin inhibitor-free graft-versus-host disease prophylaxis with sirolimus and mycophenolate mofetil in a second allogeneic stem cell transplantation for engraftment failure and rituximab-refractory Epstein-Barr virus-induced posttransplant lymphoproliferative disease.
    Ceppi F; Duval M; Teira P; Therrien R; Ovetchkine P; Mallette B; Bittencourt H
    J Pediatr Hematol Oncol; 2014 Jul; 36(5):e319-21. PubMed ID: 24977404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human leukocyte antigen type and posttransplant lymphoproliferative disorder.
    Lustberg ME; Pelletier RP; Porcu P; Martin SI; Quinion CD; Geyer SM; Caligiuri MA; Baiocchi RA
    Transplantation; 2015 Jun; 99(6):1220-5. PubMed ID: 25427163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study.
    Dharnidharka VR; Ho PL; Stablein DM; Harmon WE; Tejani AH
    Pediatr Transplant; 2002 Oct; 6(5):396-9. PubMed ID: 12390426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Post-transplantation lymphoproliferative disorders (PTLD) localized in the central nervous system: report from an international survey on PTLD.
    Khedmat H; Taheri S
    Saudi J Kidney Dis Transpl; 2013 Mar; 24(2):235-42. PubMed ID: 23538344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinicopathologic study of post-transplant lymphoproliferative disorders].
    Zhang YN; Zhou XG; Wang CZ; Wei P; Zhang SH; Zheng YY
    Zhonghua Bing Li Xue Za Zhi; 2006 Apr; 35(4):209-12. PubMed ID: 16776977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conversion from Calcineurin Inhibitor-Based Immunosuppression to Mycophenolate Mofetil in Monotherapy Reduces Risk of De Novo Malignancies After Liver Transplantation.
    Aguiar D; Martínez-Urbistondo D; D'Avola D; Iñarrairaegui M; Pardo F; Rotellar F; Sangro B; Quiroga J; Herrero JI
    Ann Transplant; 2017 Mar; 22():141-147. PubMed ID: 28302995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathologic and clinical features of Hodgkin lymphoma--like posttransplant lymphoproliferative disease.
    Krishnamurthy S; Hassan A; Frater JL; Paessler ME; Kreisel FH
    Int J Surg Pathol; 2010 Aug; 18(4):278-85. PubMed ID: 19578050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
    Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
    Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune activation, immune senescence and levels of Epstein Barr Virus in kidney transplant patients: Impact of mTOR inhibitors.
    Petrara MR; Serraino D; Di Bella C; Neri F; Del Bianco P; Brutti M; Carmona F; Ballin G; Zanini S; Rigotti P; Furian L; De Rossi A
    Cancer Lett; 2020 Jan; 469():323-331. PubMed ID: 31693921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.